Monoclonal Antibody Heavy-Chain Substitutions for Higher Titer Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Monoclonal antibodies (mAbs) face challenges in production stability and titer, leading to increased production costs and potential immunologic risks due to degradation and fragmentation.
Innovation Solution
Substituting specific amino acids at heavy chain positions 56 and/or 80 of monoclonal antibodies with glycine, alanine, serine, or hydrophobic residues like alanine, isoleucine, leucine, methionine, phenylalanine, and valine to enhance stability, measured by increased titer, yield, purity, and melting point temperature.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If monoclonal antibodies are produced in bioreactors from engineered cells, then production is achieved, but production levels are low and production costs increase
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequence of monoclonal antibodies at specific positions (heavy chain positions 56 and 80). By substituting specific amino acids (e.g., replacing position 56 with glycine, alanine, or serine; and position 80 with hydrophobic residues like valine, leucine, or phenylalanine), the invention optimizes production parameters to achieve higher titers and improved stability without proportionally increasing production costs
2Stability of the object's composition
If monoclonal antibodies are produced with standard sequences, then production is achieved, but stability is poor leading to degradation and fragmentation
Solution Approach 1:
The patent modifies the chemical composition parameters of the antibody by substituting specific amino acids at positions 56 and 80 of the heavy chain. These parameter changes enhance the structural stability of the antibody, reducing degradation and fragmentation while maintaining or improving its potency and safety profile
3Stability of the object's composition
If amino acid substitutions are made to improve stability, then stability increases, but production process complexity increases
Solution Approach 1:
The patent applies local quality by making targeted amino acid substitutions at specific local positions (56 and 80) of the heavy chain rather than modifying the entire antibody sequence. This localized approach improves stability while minimizing the complexity of the production process, as only specific residues need to be modified
Data Source
AI summary
Presented herein are methods directed to engineering monoclonal antibodies and antibody variants to improve stability and their production in culture. Specifically, the monoclonal antibodies can be engineered at heavy chain residue 56 (AHo numbering) to a glycine, alanine, or serine, and/or engineered at position 80 (AHo) to be a hydrophobic residue such as alanine, isoleucine, phenylalanine, leucine, methionine, or valine.